News and Press Releases
Press releases
Theralase Granted FDA Fast Track Designation for NMIBC Phase II Clinical Study
Toronto, Ontario –November 23, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical...
0Theralase Technology Demonstrates High Kill Rate of Coronavirus (BSL-2)
Toronto, Ontario – November 13, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...
0Theralase Releases Quarterly Newsletter
Toronto, Ontario – October 26, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company“)(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharm...
0Theralase Announces Warrant Extension
Toronto, Ontario – September 30, 2020, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmac...
0Theralase Provides Update on Bladder Cancer Study
Toronto, Ontario – September 24, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical st...
0Theralase® Releases 2Q2020 Financial Statements
Toronto, Ontario – August 28, 2020, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical s...
0Theralase Amends the Company’s Standard By-Laws
Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
0Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy
Toronto, Ontario – August 19, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
0Canadian Clinical Study Sites Re-Commence Bladder Cancer Study
Toronto, Ontario – August 12, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...
0Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study (“Study II”) Progress
Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment Toronto,...
0in the news


BTv – Theralase® an innovative medical technology for bladder cancer treatment – 2018
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.